



VALEO PHARMA™

**PRESS RELEASE  
FOR IMMEDIATE DISTRIBUTION**

## **VALEO PHARMA REPORTS ON LAUNCH OF NEW CORPORATE STRUCTURE**

- **Sales team expands to 65 bringing total employees to 95**
- **National sales structure now actively deployed in support of Enerzair® Breezhaler® and Atectura® Breezhaler®**
- **Head office and warehouse facility expanded to support sales growth**

MONTREAL, QUEBEC , August 16, 2021 – [Valeo Pharma Inc.](#) (CSE:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it has completed implementation of its new corporate structure and launched full commercial activities in support of Enerzair Breezhaler triple therapy and Atectura Breezhaler dual therapy, two new asthma medications.

The Company is now structured into 2 business units, Respiratory and Specialty Products, led by industry veterans Howard Wiseman and Jean-Charles Leathead respectively. With the completion of a full national sales structure for each business unit, Valeo’s sales team has expanded to 65 professionals out of a total of 95 full time employees. The Company has also recently expanded its head office and warehouse capacity to support its recent product launches.

“Our Respiratory business unit has deployed full commercial coverage across Canada and we are actively engaging with healthcare professionals in support of Enerzair and Atectura”, said Steve Saviuk, CEO. “Our recently completed medical team, headed by Nelly Komari, provides us with strong capabilities for our expanding portfolio of innovative drugs. Redesca®, Enerzair and Atectura are important launches for us and we expect these three products to lead our sales growth. Launched in April, Redesca has quickly become our fastest growing product line and we continue to believe that it will achieve peak revenues of \$30M annually”.

Commenting on the new corporate structure implementation completion, Frederic Fasano, Valeo’s President and Chief Operating Officer said, “We are very pleased to have been able to complete the implementation of our new corporate structure and commercially launch three transformative products in such a short period of time. This testifies to the quality of our people in place and of those recently recruited. The successful integration of our dedicated sales teams with the related supportive head office functions will create significant operating leverage over the coming years as we continue to add strategic assets to each



VALEO PHARMA™

business unit and take full advantage of our new corporate structure and commercial platform”.

### **About Valeo Pharma**

Valeo Pharma is a Canadian pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Respiratory Diseases, Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly manage its growing product portfolio through all stages of commercialization. For more information, please visit [www.valeopharma.com](http://www.valeopharma.com) and follow us on [LinkedIn](#) and [Twitter](#).

### **Forward Looking Statements**

This press release contains forward-looking statements about Valeo’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

For more information:

Steve Saviuk  
CEO  
514-693-8830  
[saviuk@valeopharma.com](mailto:saviuk@valeopharma.com)

or

Frederic Dumais  
Director, Communications and Investor Relations  
514-261-4735  
[dumais@valeopharma.com](mailto:dumais@valeopharma.com)